Production (Stage)
Fate Therapeutics, Inc.
FATE
$1.28
-$0.125-8.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.62M | -52.15M | -47.68M | -38.43M | -48.00M |
| Total Depreciation and Amortization | 3.33M | 4.81M | 4.61M | 4.72M | 4.82M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.85M | 21.45M | 10.52M | 5.19M | 9.22M |
| Change in Net Operating Assets | -5.37M | -1.91M | 3.13M | -3.79M | 614.00K |
| Cash from Operations | -33.81M | -27.80M | -29.42M | -32.31M | -33.35M |
| Capital Expenditure | -1.20M | -98.00K | -495.00K | -51.00K | -86.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 43.87M | 22.91M | 25.96M | -53.32M | 17.40M |
| Cash from Investing | 42.67M | 22.82M | 25.46M | -53.37M | 17.31M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00 | 0.00 | -- | 75.49M |
| Repurchase of Common Stock | -- | -- | -- | -666.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 3.13M | 0.00 | 1.94M | 20.00M |
| Cash from Financing | -- | 3.13M | 0.00 | 1.27M | 95.49M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.86M | -1.85M | -3.96M | -84.41M | 79.45M |